stoxline Quote Chart Rank Option Currency Glossary
  
Milestone Pharmaceuticals Inc. (MIST)
1.64  0.01 (0.61%)    04-19 16:00
Open: 1.65
High: 1.7
Volume: 29,523
  
Pre. Close: 1.63
Low: 1.62
Market Cap: 87(M)
Technical analysis
2024-04-19 5:10:56 PM
Short term     
Mid term     
Targets 6-month :  2.04 1-year :  2.31
Resists First :  1.75 Second :  1.98
Pivot price 1.73
Supports First :  1.38 Second :  1.15
MAs MA(5) :  1.7 MA(20) :  1.74
MA(100) :  1.9 MA(250) :  2.68
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  26.1 D(3) :  31.3
RSI RSI(14): 45.2
52-week High :  4.48 Low :  1.33
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ MIST ] has closed above bottom band by 10.5%. Bollinger Bands are 70% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.7 - 1.71 1.71 - 1.72
Low: 1.6 - 1.61 1.61 - 1.62
Close: 1.63 - 1.64 1.64 - 1.65
Company Description

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Headline News

Sat, 13 Apr 2024
Milestone Pharmaceuticals (NASDAQ:MIST) Stock Price Up 3.8% - MarketBeat

Thu, 21 Mar 2024
MIST Stock Earnings: Milestone Pharmaceuticals Misses EPS for Q4 2023 - InvestorPlace

Fri, 09 Feb 2024
MIST Stock Quote Price and Forecast - CNN

Tue, 16 Jan 2024
Down -43.64% in 4 Weeks, Here's Why Milestone Pharmaceuticals (MIST) Looks Ripe for a Turnaround - Yahoo Finance

Wed, 27 Dec 2023
Milestone Pharma (MIST) Down on Regulatory Update for Etripamil - Yahoo Finance

Tue, 26 Dec 2023
ROSEN, A LEADING LAW FIRM, Encourages Milestone Pharmaceuticals Inc. Investors to Inquire About Securities ... - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 53 (M)
Held by Insiders 3.392e+007 (%)
Held by Institutions 0.6 (%)
Shares Short 451 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -6.101e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -6 %
Return on Assets (ttm) 109.8 %
Return on Equity (ttm) -51.1 %
Qtrly Rev. Growth 1e+006 %
Gross Profit (p.s.) -56.5
Sales Per Share -81.14
EBITDA (p.s.) 0
Qtrly Earnings Growth -1.4 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -46 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.03
Price to Cash Flow 7.44
Stock Dividends
Dividend 0
Forward Dividend 559530
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android